BFA
NKTR icon

BlackRock Fund Advisors’s Nektar Therapeutics NKTR Stock Holding History

BlackRock Fund Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$170M Buy
922,913
+191,515
+26% +$38.9M 0.03% 773
2016
Q3 		$188M Buy
731,398
+49,966
+7% +$12.9M 0.04% 578
2016
Q2 		$145M Buy
681,432
+12,800
+2% +$2.86M 0.03% 699
2016
Q1 		$138M Buy
668,632
+11,451
+2% +$2.2M 0.03% 701
2015
Q4 		$166M Buy
657,181
+4,653
+0.7% +$957K 0.04% 587
2015
Q3 		$107M Buy
652,528
+33,263
+5% +$5.88M 0.03% 852
2015
Q2 		$116M Buy
619,265
+294,650
+91% +$50.7M 0.03% 863
2015
Q1 		$53.6M Buy
324,615
+9,058
+3% +$1.86M 0.01% 1467
2014
Q4 		$73.4M Buy
315,557
+28,484
+10% +$6.09M 0.02% 1189
2014
Q3 		$52M Sell
287,073
-11,638
-4% -$2.23M 0.01% 1341
2014
Q2 		$57.4M Sell
298,711
-25,527
-8% -$4.51M 0.02% 1310
2014
Q1 		$58.9M Buy
324,238
+35,456
+12% +$7.02M 0.02% 1292
2013
Q4 		$49.2M Sell
288,782
-3,237
-1% -$522K 0.02% 1410
2013
Q3 		$45.8M Buy
292,019
+38,975
+15% +$7.21M 0.02% 1411
2013
Q2 		$43.8M Buy
+253,044
New +$38.8M 0.02% 1317

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

BlackRock Fund Advisors's NKTR Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Nektar Therapeutics (NKTR) stake by 26% in Q4 2016, buying an estimated $38.9M and bringing the position to 922,913 shares worth $170M. The position accounts for 0.03% of the portfolio, ranked #773.

BlackRock Fund Advisors first reported a position in NKTR in Q2 2013 and has held it in 15 quarters since. The position peaked at $188M in Q3 2016. 199 funds tracked by Wall St. Rank hold NKTR as of Q4 2016.

  • BlackRock Fund Advisors held 922,913 shares of Nektar Therapeutics worth $170M as of Q4 2016.
  • BlackRock Fund Advisors bought 191,515 Nektar Therapeutics shares in Q4 2016, an estimated $38.9M.
  • Nektar Therapeutics made up 0.03% of BlackRock Fund Advisors's portfolio in Q4 2016, its #773 holding.
  • BlackRock Fund Advisors first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Fund Advisors's Nektar Therapeutics position peaked at $188M in Q3 2016.
  • 199 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.